Cecelia Health, a NYC-based technology-enabled diabetes and other chronic disease management company, closed a $13m Series B funding round.
The round was co-led by Rittenhouse Ventures and Endo Investors, with participation from Boston Millennia Partners, SustainVC, G100 Capital, and others. In conjunction with the funding, Saul Richter from Rittenhouse, and Eric Edidin from Endo Investors join the Cecelia Board.
The company intends to use the funds to accelerate and further scale the adoption of its technology enabled coaching and telemedicine solutions and expand its digital health capabilities.
Led by David Weingard, Founder and CEO, Cecelia Health has emerged as a leader in using expert clinicians that leverage a technology-enabled digital health platform. With over one million remote patient interactions, the company has been a pioneer in delivering telehealth and chronic disease management solutions.
Cecelia Health will leverage the new funding to deliver a commercial Virtual Clinic that will offer CGM training, education on medication adherence and lifestyle and behavior change, mental health screening and counseling, all supported by algorithms that will recommend necessary dosage and titration changes that will be reviewed and approved by Cecelia Health’s CDCESs and Endocrinologists. The Virtual Clinic will be supported by the company’s national network of diabetes professionals.